Peak Bio, Inc. (PKBO)

Market Cap	4.16M
Revenue (ttm)	354.02K
Net Income (ttm)	-4.63M
Shares Out	23.12M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	250
Open	0.180
Previous Close	0.175
Day's Range	0.180 - 0.180
52-Week Range	0.002 - 0.688
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 22, 2024

About Peak Bio

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with cancer, inflammatory, and rare diseases in the United States. The company’s lead product candidate is PHP-303, which is in Phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate in preclinical trials for solid tumors. Peak Bio, Inc. is based in Pleasanton, California.

• Industry: Biotechnology
• Sector: Healthcare
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: PKBO

Financial Performance

In 2023, Peak Bio's revenue was $367,877, a decrease of -39.46% compared to the previous year's $607,681. Losses were -$12.83 million, -2.01% less than in 2022.